Abstract 565P
Background
The benefit of consolidation chemotherapy (CC) and addition of gemcitabine to concomitant chemoradiotherapy for locally advanced cervical cancer (LACC) is still controversial.
Methods
This is a retrospective review of medical reports from patients with LACC treated in a Brazilian cancer center from 2012 to 2017. Patients were included if they presented FIGO2010 stages IB2 to IVB (IVB including only those with paraaortic lymph node), and were treated with radiotherapy with weekly cisplatin or cisplatin plus gemcitabine (GC) during the 6 weeks of radiotherapy treatment, followed or not by consolidation chemotherapy with cisplatin and gemcitabine for two cycles.
Results
A total of 397 cases were evaluated. With a median follow-up of 47.6 months, the median overall survival (mOS) was 88.3months for patients undergoing CC versus 73.7months for patients who were not treated with CC (p=0.139). In the multivariate analysis, CC reduced risk of death by 32% [HR= 0.68; IC95%(0.43-1.08); p= 0.109]. mOS was 87.2months for patients who were treated with CG during radiotherapy, versus 74.9months for patients who were treated with cisplatin alone (p=0.391). Median progression-free survival (mPFS) was 85.1months versus 72.1months for patients who were treated with or without CC, respectively. Three-year PFS was 78.2% versus 78.5% for patients treated with CG compared to those treated with cisplatin alone during radiotherapy (p=0.918). In a subgroup analysis, the addition of CC in stage IIIA-IVB improved overall survival, 80.6 months versus 62.2 months (p=0.022), but not PFS (p=0.255).
Conclusions
The present study did not show a benefit from the addition of consolidation chemotherapy in patients with LACC treated with definitive chemoradiotherapy.The subgroup analysis raises the possibility that patients with more advanced disease may benefit from the addition of consolidation chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.